ποΈ
Archived grant β no longer open
This grant has closed and is kept as a historical reference. Browse current grants for active opportunities.
grant
Proteomic determinants of response to checkpoint blockade in malignant pleural mesothelioma
Organization UNIVERSITY OF CALIFORNIA LOS ANGELESLocation LOS ANGELES, UNITED STATESPosted 1 Jan 2021Deadline 31 Dec 2025 β οΈ
NIHUS FederalResearch GrantFY2025AccelerationAntigen TargetingArchitectureAtlasesB7-H1BioinformaticsBiological MarkersBiologyBody TissuesCD274Cancer TreatmentCancersCaringCell BodyCell Communication and SignalingCell SignalingCellsCheckpoint inhibitorClinicalClinical DataClinical MarkersCytometryDataDiseaseDisorderDrugsElementsEngineering / ArchitectureFormalinFrequenciesHLA testingHLA typingHumanImageImmuneImmune checkpoint inhibitorImmunesImmunochemical ImmunologicImmunohistochemistryImmunohistochemistry Cell/TissueImmunohistochemistry Staining MethodImmunologicImmunologicalImmunologicallyImmunologicsIntracellular Communication and SignalingIntratumoral heterogeneityLifeLife ExtensionLungLung Respiratory SystemMHC antigenMalignant Mesothelioma of the PleuraMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant Pleural MesotheliomaMalignant Pleural NeoplasmMalignant Pleural TumorMalignant TumorMass Photometry/Spectrum AnalysisMass SpectrometryMass SpectroscopyMass SpectrumMass Spectrum AnalysesMass Spectrum AnalysisMeasuresMedicationModern ManNivolumabOpdivoOperative ProceduresOperative Surgical ProceduresPD-1 antibodyPD-1 blockadePD-L1PD1 antibodyPD1 blockadePDL-1PLRAParaffin EmbeddingPatient CarePatient Care DeliveryPatientsPeptidesPharmaceutical PreparationsPhenotypePleuraPleura CancerPleural CancerPleural TissueProductionProgrammed Cell Death 1 Ligand 1Programmed Death Ligand 1Prospective cohortProtein AnalysisProteinsProteomicsRNA SeqRNA sequencingRNAseqRadiation therapyRadiotherapeuticsRadiotherapyResearch SpecimenResistanceSamplingSignal TransductionSignal Transduction SystemsSignalingSpecimenStructureSurgicalSurgical InterventionsSurgical ProcedureT cell responseT-CellsT-LymphocyteTechniquesTestingTimeTissuesToxic effectToxicitiesTranslatingTriageTumor BurdenTumor LoadValidationaPD-1aPD1abstractinganti programmed cell death 1anti-PD-1anti-PD-1 Abanti-PD-1 antibodiesanti-PD-1 blockadeanti-PD-1 monoclonal antibodiesanti-PD1anti-PD1 Abanti-PD1 antibodiesanti-PD1 blockadeanti-PD1 monoclonal antibodiesanti-cancer therapyanti-programmed cell death protein 1anti-programmed cell death protein 1 antibodiesanti-programmed death-1 antibodyantiPD-1antigen based detectionantigen detectionbio-informatics pipelinebio-markersbioinformatics pipelinebiologic markerbiological signal transductionbiomarkercancer therapycancer-directed therapycare for patientscare of patientscaring for patientscell typecheck point blockadecheckpoint blockadechemotherapyclinical applicabilityclinical applicationclinical biomarkersclinical translationclinically translatableclinically useful biomarkerscohortcostcytokinedesigndesigningdetect antigendrug/agenteffective therapyeffective treatmentexome sequencingexome-seqheterogeneity in tumorshigh dimensionalityhuman leukocyte antigen testinghuman leukocyte antigen typingimagingimmune check point blockadeimmune check point inhibitorimmune checkpoint blockadeimmune microenvironmentimmunogenicityimmunosuppressive microenvironmentimmunosuppressive tumor microenvironmentimprovedin silicoindexinginnovateinnovationinnovativeintra-tumoral heterogeneityintratumor heterogeneitymalignancymalignant pleura neoplasmmalignant pleura tumorneo-antigenneo-epitopesneoantigensneoepitopesneoplasm/cancernew markernovelnovel biomarkernovel markerpredict responsivenesspredicting responsepredictive biological markerpredictive biomarkerspredictive markerpredictive molecular biomarkerprogrammed cell death ligand 1programmed cell death protein ligand 1prospectiveprospective testprotein death-ligand 1radiation treatmentresistantresponders and non-respondersresponders from non-respondersresponders or non-respondersresponders versus non-respondersresponders vs non-respondersresponders/nonrespondersresponseside effectsingle cell analysisstandard of caresurgerythymus derived lymphocytetime usetraditional therapytranscriptome sequencingtranscriptomic sequencingtreatment with radiationtumortumor heterogeneitytumor immune microenvironmenttumor-immune system interactionsvalidationsΞ±PD-1Ξ±PD1
Applications closed.
Description preview
PROJECT SUMMARY / ABSTRACT
Malignant pleural mesothelioma (MPM) is a fatal cancer of the lining of the lungs that has defeated standard
therapies for decades. Immune checkpoint inhibitors (ICIs) are revolutionizing cancer treatment, and tumor-
specific neoantigens are critical components of the vigorous anti-tumor T cell responses possible fromβ¦
π
Start 7-day free trial β $29.99/mo βFull details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link β plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more β with email alerts and pipeline tracking.
$29.99 / month
- πEmail alerts for new matching tenders
- ποΈTrack tenders in your pipeline
- π°Filter by contract value
- π₯Export results to CSV
- πSave searches with one click